LONDON–(BUSINESS WIRE)–#Biotechnology–According to Technavio Research Report “Parasitic Diseases
Therapeutics Market by type (antiprotozoal therapeutics, anthelminthic
therapeutics, scabicides, and pediculicides therapeutics) and geographic
regions (Asia, ROW, North America, and Europe) is witnessed to
grow USD 1.79 billion, at a CAGR of 5% from 2019 to 2023”.
Free sample report contains market size and forecast, drivers,
challenges, trends, and more –
Request for Sample @ https://www.technavio.com/talk-to-us?report=Global+Parasitic+Diseases+Therapeutics+Market+2019-2023&type=sample&src=report
Global Parasitic Diseases Therapeutics Market:
Increasing adoption of prophylactic treatment
The prophylactic treatment has been designed to prevent the rise and
spread of parasitic diseases. Preventative chemotherapy is used to
control the transmission of helminthic infections within a community.
Also, vendors in the market are developing vaccines to prevent and
control chronic health conditions, including malaria and other diseases.
Furthermore, researchers are evaluating physically attenuated parasites
in a vaccine to control and prevent conditions, including Leishmaniasis
donovani and Leishmaniasis braziliensi. Thus, the increasing
adoption of prophylactic vaccines to prevent and control parasitic
diseases will accelerate the parasitic diseases therapeutics market
growth during the forecast period.
“Increasing initiatives to eliminate parasitic diseases globally will
drive the parasitic diseases therapeutics market growth during the
forecast period. Vendors are in partnerships that seek to support
malaria-endemic countries in eliminating malaria. Such partnership will
lead to the introduction and use of effective tools such as malaria
diagnostics, blood-stage drugs, and liver-stage radical-cure drugs which
will boost the parasitic disease therapeutics market,” says a senior
research analyst at Technavio.
Speak to Research Expert @ https://www.technavio.com/talk-to-us?report=Global+Parasitic+Diseases+Therapeutics+Market+2019-2023&type=customization
Global Parasitic Diseases Therapeutics Market:
Segmentation analysis
This market research report segments the global parasitic diseases
therapeutics market by type (antiprotozoal therapeutics, anthelminthic
therapeutics, scabicides, and pediculicides therapeutics) and geographic
regions (Asia, ROW, North America, and Europe).
Asia led the market in 2018, followed by ROW, North America, and Europe
respectively. The market growth in Asia can be attributed to the rising
prevalence of parasitic diseases. Increase in funding and initiatives
for preventing and controlling parasitic diseases will drive the market
growth in the region.
Global Parasitic Diseases Therapeutics Market:
Rising incidences of parasitic infections
Parasitic diseases are infectious and transmitted through parasites,
including protozoa, helminths, and ectoparasites. Rising incidence of
parasitic infections caused by these organisms will lead to market
growth during the forecast period. Chronic health conditions such as
Chagas disease and Schistosomiasis are highly prevalent across several
emerging economies, including Central America, South America, Mexico,
Africa, and the Caribbean. As a result, growing instances of parasitic
infections are likely to foster the parasitic diseases therapeutics
market growth during the forecast period.
Few Major Players for the Parasitic Diseases Therapeutics Market are:
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Pfizer Inc.
- Sanaria Inc.
Browse Industries Reports @ Pharmaceuticals,
Biotechnology & Life Sciences
About Technavio
Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team
at media@technavio.com.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com